| Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies M London, E Gallo Cell biology international 44 (6), 1267-1282, 2020 | 61 | 2020 |
| Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma MA Qazi, P Vora, C Venugopal, J Adams, M Singh, A Hu, M Gorelik, ... Cancer Research 78 (17), 5023-5037, 2018 | 46 | 2018 |
| Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics M London, E Gallo Molecular Biology Reports 47 (7), 5523-5533, 2020 | 27 | 2020 |
| The EphA2 and cancer connection: potential for immune-based interventions M London, E Gallo Molecular Biology Reports 47 (10), 8037-8048, 2020 | 20 | 2020 |
| Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma P Vora, C Chokshi, M Qazi, C Venugopal, S Mahendram, M Singh, ... Cancer Immunology Research 4 (11_Supplement), B079-B079, 2016 | 3 | 2016 |
| System and method for profiling antibodies with high-content screening (hcs) S Cooper, O Kraus, M London, G Watson, A Nixon, E Koch, È Dumoulin, ... US Patent App. 17/918,882, 2023 | | 2023 |
| AI/ML-driven discovery of a novel proteoglycan for precision targeting of ADCs for disruption of stromal barriers and direct anti-tumor activity E Koch, M London, A Berkley, A Nixon, S Phippen, K White, A Hanson, ... Cancer Research 82 (12_Supplement), 388-388, 2022 | | 2022 |
| 1350 AI/ML-driven discovery of Collagen Triple Helix Repeat-Containing 1, CTHRC1, a novel proteoglycan for disruption of stromal barriers and enhancement of immunotherapy … E Koch, A Berkley, S Phippen, M London, K White, A Hanson J Immunother 10 (2), A1-A1595, 2022 | | 2022 |
| BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies P Vora, J Adams, M Singh, C Venugopal, N Tatari, C Chokshi, M Qazi, ... Cancer Research 78 (13_Supplement), 1763-1763, 2018 | | 2018 |
| Epha2 and epha3-binding agents and uses thereof S Sidhu, G Pan, J ADAMS, J MOFFAT, ME LONDON, M GORELIK, ... | | 2018 |
| Phage Display for the Development of Synthetic Antibodies Targeting Receptor Tyrosine Kinases ME London University of Toronto (Canada), 2018 | | 2018 |
| Identification and Co-Targeting of EphA2/EphA3 Cancer Stem Cells in Recurrent Human Glioblastoma MA Qazi, P Vora, C Venugopal, J Adams, M Singh, A Hu, M Gorelik, ... | | 2018 |
| Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma M Qazi, P Vora, C Chokshi, C Venugopal, M London, A Hu, ... Cancer Research 77 (13 Supplement), 3639-3639, 2017 | | 2017 |
| The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma P Vora, C Chokshi, M Qazi, M Singh, C Venugopal, S Mahendram, ... Cancer Research 77 (13_Supplement), 3758-3758, 2017 | | 2017 |
| Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma P Vora, M Qazi, C Chokshi, C Venugopal, M London, A Hu, N McFarlane, ... Cancer Immunology Research 4 (11_Supplement), B092-B092, 2016 | | 2016 |
| Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma P Vora, M Qazi, C Chokshi, C Venugopal, M London, A Hu, N McFarlane, ... CANCER IMMUNOLOGY RESEARCH 4 (11), 2016 | | 2016 |
| PS2-172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells P Vora, C Venugopal, C Choksi, M Qazi, J Adams, M London, ... Canadian Journal of Neurological Sciences 43 (S4), S13-S14, 2016 | | 2016 |
